MET exon 14-altered lung cancers and MET inhibitor resistance

PURPOSE: MET tyrosine kinase inhibitors (TKIs) can achieve modest clinical outcomes in MET exon 14-altered lung cancers, likely secondary to primary resistance. Mechanisms of primary resistance remain poorly characterized and comprehensive proteomic analyses have not previously been performed. EXPER...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Clin Cancer Res
Main Authors: Guo, Robin, Offin, Michael, Brannon, A. Rose, Chang, Jason, Chow, Andrew, Delasos, Lukas, Girshman, Jeffrey, Wilkins, Olivia, McCarthy, Caroline G., Makhnin, Alex, Falcon, Christina, Scott, Kerry, Tian, Yuan, Cecchi, Fabiola, Hembrough, Todd, Alex, Deepu, Shen, Ronglai, Benayed, Ryma, Li, Bob T., Rudin, Charles M., Kris, Mark G., Arcila, Maria E., Rekhtman, Natasha, Paik, Paul, Zehir, Ahmet, Drilon, Alexander
Formato: Artigo
Idioma:Inglês
Publicado: 2020
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7854494/
https://ncbi.nlm.nih.gov/pubmed/33172896
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-20-2861
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares